TransMedics Group, Inc. has disclosed recent stock transactions by its director, James R. Tobin, which may influence shareholder perceptions and the company's market position.

Company Overview

TransMedics Group, Inc. operates in the electromedical and electrotherapeutic apparatus sector, as categorized under SIC 3845. The company is publicly traded on the Nasdaq under the ticker symbol TMDX. Its headquarters is located in Andover, Massachusetts, where it focuses on innovative solutions in the medical field.

What the Filing Says

In a filing dated November 12, 2026, Tobin reported selling 4,059 shares of common stock on November 9, 2026, at prices ranging from $94.98 to $95.01. Following these transactions, he retains ownership of 155,146 shares, with 6,922 shares directly owned after the sale. The filing notes, "The price reported is a weighted average price. These shares were sold in multiple transactions." This detail highlights the active management of his holdings.

Impact

The transactions reported by Tobin could affect shareholder sentiment as they reflect the director's decisions regarding his investment in TransMedics. As a significant figure in the company, his actions may be closely monitored by investors and analysts alike, especially in the context of the company's performance and market conditions.

What's Next

The filing does not say what happens next.